OBJECTIVE: To construct a humanized mouse model of systemic lupus erythematosus (SLE) that resembles the human disease in order to define the pathophysiology and targets for treatments. METHODS: We infused peripheral blood mononuclear cells (PBMCs) from SLE patients into BALB- RAG-2-/- IL-2Rγ-/- double-knockout (DKO) mice, which lack T cells, B cells, and natural killer cells. PBMCs from 5 SLE patients and 4 normal donors were infused intravenously/intraperitoneally at a density of 3-5×10(6) cells per animal into nonirradiated 4-5-week-old mice. We evaluated the engraftment of human CD45+ cells and monitored the plasma levels of human IgG, anti-double-stranded DNA (anti-dsDNA) antibody, and anticardiolipin antibody (aCL), as well as proteinuria and kidney histology. RESULTS: There was 100% successful engraftment in 40 DKO mice infused with human PBMCs. In the PBMC fraction from SLE PBMC-infused DKO (SLE-DKO) mice and normal donor PBMC-infused DKO (ND-DKO) mice, an average of 41% and 53% human CD45+ cells, respectively, were observed at 4 weeks postengraftment, with 70-90% CD3+ cells. There were fewer CD3+CD4+ cells (mean±SEM 5.5±2.1%) and more CD3+CD8+ cells (79.4±3.6%) in the SLE-DKO mice as in the SLE patients from which the PBMCs were derived. CD19+ B cells and CD11c+ monocytic cells were found in the spleen, lung, liver, and bone marrow. There was no significant difference in plasma levels of human IgG and anti-dsDNA antibodies between SLE-DKO and ND-DKO mice. Levels of aCL were significantly higher in all SLE-DKO mice infused with PBMCs from an SLE patient who had high titers of aCL. SLE-DKO mice had proteinuria, human IgG deposits in the kidneys, and a shorter life span. In SLE-DKO mice engrafted with PBMCs from the aCL-positive patient, we found microthrombi and infiltration of CD3+, CD8+, and CD19+ cells in the glomeruli, recapitulating the human antiphospholipid syndrome in these mice. CONCLUSION: We established a novel humanized SLE-DKO mouse exhibiting many of the immunologic and clinical features of human SLE.
OBJECTIVE: To construct a humanized mouse model of systemic lupus erythematosus (SLE) that resembles the human disease in order to define the pathophysiology and targets for treatments. METHODS: We infused peripheral blood mononuclear cells (PBMCs) from SLEpatients into BALB- RAG-2-/- IL-2Rγ-/- double-knockout (DKO) mice, which lack T cells, B cells, and natural killer cells. PBMCs from 5 SLEpatients and 4 normal donors were infused intravenously/intraperitoneally at a density of 3-5×10(6) cells per animal into nonirradiated 4-5-week-old mice. We evaluated the engraftment of humanCD45+ cells and monitored the plasma levels of humanIgG, anti-double-stranded DNA (anti-dsDNA) antibody, and anticardiolipin antibody (aCL), as well as proteinuria and kidney histology. RESULTS: There was 100% successful engraftment in 40 DKO mice infused with human PBMCs. In the PBMC fraction from SLEPBMC-infused DKO (SLE-DKO) mice and normal donorPBMC-infused DKO (ND-DKO) mice, an average of 41% and 53% humanCD45+ cells, respectively, were observed at 4 weeks postengraftment, with 70-90% CD3+ cells. There were fewer CD3+CD4+ cells (mean±SEM 5.5±2.1%) and more CD3+CD8+ cells (79.4±3.6%) in the SLE-DKOmice as in the SLEpatients from which the PBMCs were derived. CD19+ B cells and CD11c+ monocytic cells were found in the spleen, lung, liver, and bone marrow. There was no significant difference in plasma levels of humanIgG and anti-dsDNA antibodies between SLE-DKO and ND-DKO mice. Levels of aCL were significantly higher in all SLE-DKOmice infused with PBMCs from an SLEpatient who had high titers of aCL. SLE-DKOmice had proteinuria, humanIgG deposits in the kidneys, and a shorter life span. In SLE-DKOmice engrafted with PBMCs from the aCL-positive patient, we found microthrombi and infiltration of CD3+, CD8+, and CD19+ cells in the glomeruli, recapitulating the humanantiphospholipid syndrome in these mice. CONCLUSION: We established a novel humanized SLE-DKOmouse exhibiting many of the immunologic and clinical features of humanSLE.
Authors: R Araki; A Fujimori; K Hamatani; K Mita; T Saito; M Mori; R Fukumura; M Morimyo; M Muto; M Itoh; K Tatsumi; M Abe Journal: Proc Natl Acad Sci U S A Date: 1997-03-18 Impact factor: 11.205
Authors: Y Shinkai; G Rathbun; K P Lam; E M Oltz; V Stewart; M Mendelsohn; J Charron; M Datta; F Young; A M Stall Journal: Cell Date: 1992-03-06 Impact factor: 41.582
Authors: Hania Kebir; Lionel Carmant; François Fontaine; Kathie Béland; Ciprian M Bosoi; Nathalie T Sanon; Jorge I Alvarez; Sébastien Desgent; Camille L Pittet; David Hébert; Marie-Josée Langlois; Rose-Marie Rébillard; Dang K Nguyen; Cécile Cieuta-Walti; Gregory L Holmes; Howard P Goodkin; John R Mytinger; Mary B Connolly; Alexandre Prat; Elie Haddad Journal: J Clin Invest Date: 2018-04-09 Impact factor: 14.808
Authors: Mahiuddin Ahmed; Andres Lopez-Albaitero; Dmitry Pankov; Brian H Santich; Hong Liu; Su Yan; Jingyi Xiang; Pei Wang; Aisha N Hasan; Annamalai Selvakumar; Richard J O'Reilly; Cheng Liu; Nai-Kong V Cheung Journal: JCI Insight Date: 2018-02-22
Authors: N Mihaylova; P Chipinski; S Bradyanova; T Velikova; E Ivanova-Todorova; S Chausheva; M Herbáth; D Kalinova; J Prechl; D Kyurkchiev; A I Tchorbanov Journal: Clin Exp Immunol Date: 2019-12-04 Impact factor: 4.330
Authors: Nicole C Walsh; Laurie L Kenney; Sonal Jangalwe; Ken-Edwin Aryee; Dale L Greiner; Michael A Brehm; Leonard D Shultz Journal: Annu Rev Pathol Date: 2016-12-05 Impact factor: 23.472